Cargando…
Changes in peripheral monocyte populations 48-72 hours after subcutaneous denosumab administration in women with osteoporosis
OBJECTIVES: To examine the effect of denosumab administration in the peripheral blood white cell population, to further elucidate a plausible pathophysiological link between denosumab and osteonecrosis of the jaw. METHODS: Thirty women with osteoporosis, after denosumab treatment were included. Peri...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
International Society of Musculoskeletal and Neuronal Interactions
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7493451/ https://www.ncbi.nlm.nih.gov/pubmed/32877971 |
_version_ | 1783582571078090752 |
---|---|
author | Kyrgidis, Athanassios Yavropoulou, Maria P. Zikos, Petros Lagoudaki, Roza Tilaveridis, Jannis Zouloumis, Lambros |
author_facet | Kyrgidis, Athanassios Yavropoulou, Maria P. Zikos, Petros Lagoudaki, Roza Tilaveridis, Jannis Zouloumis, Lambros |
author_sort | Kyrgidis, Athanassios |
collection | PubMed |
description | OBJECTIVES: To examine the effect of denosumab administration in the peripheral blood white cell population, to further elucidate a plausible pathophysiological link between denosumab and osteonecrosis of the jaw. METHODS: Thirty women with osteoporosis, after denosumab treatment were included. Peripheral blood samples were obtained prior to and 48-72 hours following denosumab administration. Flow cytometry gated at the monocyte population for CD14/CD23/CD123/CD16 stainings were performed. RESULTS: We were able to record a number of changes in the monocyte populations between baseline and after denosumab administration. Most importantly, in the monocyte populations we were able to detect statistically significant increased populations of CD14+/CD23+ (p=0.044), CD14-/CD23+ (p=0.044), CD14+/CD123+ (p=0.011), CD14+/CD123- (p=0.011) and CD14-/CD16+ (p=0.028). In contrast, statistically significant decreased populations of CD14-/CD123+ (p=0.034), CD14+/CD16+ (p=0.037) and CD14+/CD16- (p=0.014) were detected. CONCLUSIONS: Our results provide evidence supporting the hypothesis that denosumab administration modifies the monocyte mediated immune response in a manner similar to that of bisphosphonates. This may partly explain the trivial immunity changes recorded with denosumab. |
format | Online Article Text |
id | pubmed-7493451 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | International Society of Musculoskeletal and Neuronal Interactions |
record_format | MEDLINE/PubMed |
spelling | pubmed-74934512020-09-21 Changes in peripheral monocyte populations 48-72 hours after subcutaneous denosumab administration in women with osteoporosis Kyrgidis, Athanassios Yavropoulou, Maria P. Zikos, Petros Lagoudaki, Roza Tilaveridis, Jannis Zouloumis, Lambros J Musculoskelet Neuronal Interact Original Article OBJECTIVES: To examine the effect of denosumab administration in the peripheral blood white cell population, to further elucidate a plausible pathophysiological link between denosumab and osteonecrosis of the jaw. METHODS: Thirty women with osteoporosis, after denosumab treatment were included. Peripheral blood samples were obtained prior to and 48-72 hours following denosumab administration. Flow cytometry gated at the monocyte population for CD14/CD23/CD123/CD16 stainings were performed. RESULTS: We were able to record a number of changes in the monocyte populations between baseline and after denosumab administration. Most importantly, in the monocyte populations we were able to detect statistically significant increased populations of CD14+/CD23+ (p=0.044), CD14-/CD23+ (p=0.044), CD14+/CD123+ (p=0.011), CD14+/CD123- (p=0.011) and CD14-/CD16+ (p=0.028). In contrast, statistically significant decreased populations of CD14-/CD123+ (p=0.034), CD14+/CD16+ (p=0.037) and CD14+/CD16- (p=0.014) were detected. CONCLUSIONS: Our results provide evidence supporting the hypothesis that denosumab administration modifies the monocyte mediated immune response in a manner similar to that of bisphosphonates. This may partly explain the trivial immunity changes recorded with denosumab. International Society of Musculoskeletal and Neuronal Interactions 2020 /pmc/articles/PMC7493451/ /pubmed/32877971 Text en Copyright: © Journal of Musculoskeletal and Neuronal Interactions http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 4.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Kyrgidis, Athanassios Yavropoulou, Maria P. Zikos, Petros Lagoudaki, Roza Tilaveridis, Jannis Zouloumis, Lambros Changes in peripheral monocyte populations 48-72 hours after subcutaneous denosumab administration in women with osteoporosis |
title | Changes in peripheral monocyte populations 48-72 hours after subcutaneous denosumab administration in women with osteoporosis |
title_full | Changes in peripheral monocyte populations 48-72 hours after subcutaneous denosumab administration in women with osteoporosis |
title_fullStr | Changes in peripheral monocyte populations 48-72 hours after subcutaneous denosumab administration in women with osteoporosis |
title_full_unstemmed | Changes in peripheral monocyte populations 48-72 hours after subcutaneous denosumab administration in women with osteoporosis |
title_short | Changes in peripheral monocyte populations 48-72 hours after subcutaneous denosumab administration in women with osteoporosis |
title_sort | changes in peripheral monocyte populations 48-72 hours after subcutaneous denosumab administration in women with osteoporosis |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7493451/ https://www.ncbi.nlm.nih.gov/pubmed/32877971 |
work_keys_str_mv | AT kyrgidisathanassios changesinperipheralmonocytepopulations4872hoursaftersubcutaneousdenosumabadministrationinwomenwithosteoporosis AT yavropouloumariap changesinperipheralmonocytepopulations4872hoursaftersubcutaneousdenosumabadministrationinwomenwithosteoporosis AT zikospetros changesinperipheralmonocytepopulations4872hoursaftersubcutaneousdenosumabadministrationinwomenwithosteoporosis AT lagoudakiroza changesinperipheralmonocytepopulations4872hoursaftersubcutaneousdenosumabadministrationinwomenwithosteoporosis AT tilaveridisjannis changesinperipheralmonocytepopulations4872hoursaftersubcutaneousdenosumabadministrationinwomenwithosteoporosis AT zouloumislambros changesinperipheralmonocytepopulations4872hoursaftersubcutaneousdenosumabadministrationinwomenwithosteoporosis |